Abstract
This review describes the clinical relevance of the two drug transporters P-glycoprotein (Pgp) and multidrug resistance-associated protein (MRP) and the in vitro phenomenon which is referred to as multidrug resistance (MDR). The attempts to try to block these resistance mechanisms are summarized with specific attention for the intentionally designed 'second generation' MDR-convertors. Potential explanations of the limited clinical success rate are given and recommendations for the design of future studies provided.
Original language | English |
---|---|
Pages (from-to) | 205-220 |
Number of pages | 16 |
Journal | Investigational New Drugs |
Volume | 18 |
Issue number | 3 |
DOIs | |
Publication status | Published - 1 Jan 2000 |
Externally published | Yes |